Cargando…
DELIVER: Extending the benefits of SGLT-2 inhibitors
The DELIVER trial investigated the efficacy and safety of dapagliflozin in patients with heart failure and preserved or mildly reduced ejection fraction. The trial demonstrated that dapagliflozin significantly reduced the risk of worsening heart failure or cardiovascular death compared to placebo. T...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Magdi Yacoub Heart Foundation
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422874/ https://www.ncbi.nlm.nih.gov/pubmed/37575288 http://dx.doi.org/10.21542/gcsp.2023.21 |